Xuanzhu Biopharmaceutical (2575) Announces Proposed H Share Full Circulation Plan

Bulletin Express11-14

Xuanzhu Biopharmaceutical Co., Ltd. (2575) has disclosed a proposed plan to implement the H Share full circulation in alignment with the guidelines issued by the China Securities Regulatory Commission (CSRC). The plan involves converting 357,245,794 currently unlisted shares, accounting for approximately 68.9733% of total issued shares, into H shares.

The board of directors considered and approved the full circulation plan on November 14, 2025. After obtaining necessary regulatory approvals and filings, the company intends to apply to the Stock Exchange of Hong Kong for the listing of the converted shares on the Main Board. According to the company’s articles of association, the conversion and listing do not require approval from a shareholders’ general meeting.

As of the announcement date, the company has not yet filed a formal application with the CSRC. The final number of shares to be converted, along with the plan’s completion timeline, remains subject to regulatory processes. Further updates will be released as appropriate, and shareholders and potential investors are advised to exercise caution when trading the company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120398663?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 16:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120398663","market":"hk","top_or_hot":-1,"title":"Xuanzhu Biopharmaceutical (2575) Announces Proposed H Share Full Circulation Plan","media":"Bulletin Express","content":"<p>Xuanzhu Biopharmaceutical Co., Ltd. (2575) has disclosed a proposed plan to implement the H Share full circulation in alignment with the guidelines issued by the China Securities Regulatory Commission (CSRC). The plan involves converting 357,245,794 currently unlisted shares, accounting for approximately 68.9733% of total issued shares, into H shares.</p>\n<p>The board of directors considered and approved the full circulation plan on November 14, 2025. After obtaining necessary regulatory approvals and filings, the company intends to apply to the Stock Exchange of Hong Kong for the listing of the converted shares on the Main Board. According to the company’s articles of association, the conversion and listing do not require approval from a shareholders’ general meeting.</p>\n<p>As of the announcement date, the company has not yet filed a formal application with the CSRC. The final number of shares to be converted, along with the plan’s completion timeline, remains subject to regulatory processes. Further updates will be released as appropriate, and shareholders and potential investors are advised to exercise caution when trading the company’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xuanzhu Biopharmaceutical (2575) Announces Proposed H Share Full Circulation Plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXuanzhu Biopharmaceutical (2575) Announces Proposed H Share Full Circulation Plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-14 16:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Xuanzhu Biopharmaceutical Co., Ltd. (2575) has disclosed a proposed plan to implement the H Share full circulation in alignment with the guidelines issued by the China Securities Regulatory Commission (CSRC). The plan involves converting 357,245,794 currently unlisted shares, accounting for approximately 68.9733% of total issued shares, into H shares.</p>\n<p>The board of directors considered and approved the full circulation plan on November 14, 2025. After obtaining necessary regulatory approvals and filings, the company intends to apply to the Stock Exchange of Hong Kong for the listing of the converted shares on the Main Board. According to the company’s articles of association, the conversion and listing do not require approval from a shareholders’ general meeting.</p>\n<p>As of the announcement date, the company has not yet filed a formal application with the CSRC. The final number of shares to be converted, along with the plan’s completion timeline, remains subject to regulatory processes. Further updates will be released as appropriate, and shareholders and potential investors are advised to exercise caution when trading the company’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02575","symbol_name":"轩竹生物-B","start_time":0,"source_url":"","article_id":"1120398663","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120398663","pubTimestamp":1763110524,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Xuanzhu Biopharmaceutical Co., Ltd. (2575) has disclosed a proposed plan to implement the H Share full circulation in alignment with the guidelines issued by the China Securities Regulatory...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02575":"轩竹生物-B"},"translate_title":"轩竹生物制药(2575)公布建议H股全流通计划","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02575":1},"content_text":"Xuanzhu Biopharmaceutical Co., Ltd. (2575) has disclosed a proposed plan to implement the H Share full circulation in alignment with the guidelines issued by the China Securities Regulatory Commission (CSRC). The plan involves converting 357,245,794 currently unlisted shares, accounting for approximately 68.9733% of total issued shares, into H shares.\nThe board of directors considered and approved the full circulation plan on November 14, 2025. After obtaining necessary regulatory approvals and filings, the company intends to apply to the Stock Exchange of Hong Kong for the listing of the converted shares on the Main Board. According to the company’s articles of association, the conversion and listing do not require approval from a shareholders’ general meeting.\nAs of the announcement date, the company has not yet filed a formal application with the CSRC. The final number of shares to be converted, along with the plan’s completion timeline, remains subject to regulatory processes. Further updates will be released as appropriate, and shareholders and potential investors are advised to exercise caution when trading the company’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120398663","isCrawlerRequest":true}